But the rapid scaling-up also threatened to introduce new challenges. With global demand for pain medication on the rise, Johnson Matthey decided to grow its extractive operations.
Resolving production challenges threatening a 'strategic growth area' As scientists learn more about the benefits of managing pain – and how the risks associated with controlled substances can be safely minimized – research partners like Johnson Matthey are advancing science by innovating not only pharmaceutical ingredients but the processes by which they are made.
Johnson Matthey’s active ingredients are now found in a wide range of pain therapies, from the tramadol or codeine prescribed to patients with rheumatoid arthritis to the hydromorphone that might be used on cancer wards or in palliative care. With a 200-year history in controlled substance manufacturing, Johnson Matthey was among the first to develop the natural product extraction and chemical synthesis methods for opiates that remain at the forefront of the industry today. Johnson Matthey, a global leader in science that enables a cleaner and healthier world, is now one of the world’s leading manufacturers of opiate alkaloids, a family of compounds that serve as the active ingredient in most pain medication formulations. Medical practitioners view integrated pain management as a central part of a patient’s overall recovery plan, with research linking shorter recovery times and improved quality of life outcomes with better managed pain. He is a Chartered Accountant with a degree in Chemical Engineering.With an estimated one in five adults around the world now living with chronic or acute pain, the development of better long-term treatment regimens has become a true public health priority. Previously he was Group Finance Director of WS Atkins plc and a Non-Executive Director at Aggreko plc. He joined Johnson Matthey as Group Finance Director in 2009. FIRM PROFILE Robert was appointed as Chief Executive in June 2014. We place importance on relationships internally and externally, treating others with respect and care. We do what we say we’ll do, expect the same of each other and speak up when there’s a problem. Acting with integrity We do the right thing, for people and for the world. Our vision is for a world that’s cleaner and healthier, today and for future generations. Protecting people and the planet We practise the highest standards of health and safety, promote wellbeing for people both inside and outside of work, and seek to safeguard our planet. They guide how we do things in JM and shape the right culture to achieve our strategy. Our values Our five core values provide the framework against which we engage with each other, with our customers and with our stakeholders. Take a closer look at four of our most recent, innovative products, the advanced SCR, Fischer-Tropsch technology, the drug linker for IMMU-32 and eLNO®, which will give you an insight into the challenges we face and the incredible work that goes on at JM. Thanks to our dedicated people and expertise in science at the atomic scale, our products are progressing our strategy to help make the world a cleaner and healthier place, today and for future generations.
Our strategy in action We are continuing to innovate with science-led products that meet a critical need for society, consumers and our customers.
Through continued investment in sound research and development, we’re tackling the world’s big challenges into our third century and beyond. We’ve been leaders in our field for more than 200 years, applying unrivalled scientific expertise to enable cleaner air, improved health and the more efficient use of our planet’s natural resources. 62 CEO Today United Kingdom Awards 2019 CHEMICALS ROBERT MACLEOD CEO of Johnson Matthey FIRM PROFILE As a global leader in sustainable technologies, we apply our cutting-edge science to create solutions with our customers that make a real difference to the world around us.
0 kommentar(er)
